BRAF and neoplasm: In contrast, the success of dabrafenib plus trametinib in BRAF-mutant ATC demonstrates that targeted therapy can achieve profound tumor regression (136), while emerging evidence suggests MAPK inhibition may also favorably remodel the TIME.